The pioneering AbiProt® technology is a completely new concept in antibody discovery. It has proven capabilities to deliver antibodies against clinically meaningful targets, previously undruggable with conventional antibody technologies. AbiProt® is a scalable breakthrough innovation with potential to impact the lives of millions of patients. Some call it a revolution, we call it magic.About AbiProt®
We focus on developing new antibody medicines in pain and aggressive-metastatic cancer. These conditions are in strong need of effective therapies that can only be solved by breakthrough science and innovation. The AbiProt® technology has proven to deliver precision antibodies against clinically meaningful targets in these two disease areas.
We are a team of pharma professionals and young talent with strong scientific and business acumen. We have a proven track record of bringing drugs to the market, excellence in science, and product development. We are devoted to change the life of patients through innovation.About our Team
Recent newsMore news
08 March 2023 News
SwedenBIO launches the long-awaited 2023 edition of the large, recurring mapping of the Swedish pharmaceutical pipeline.
08 February 2023 News
30 January 2023 Event
Virtual Business development and Licensing event - Feb 6 -10, 2023